Young D W, Lever R S, English J S, MacKie R M
Cancer. 1985 May 1;55(9):1879-81. doi: 10.1002/1097-0142(19850501)55:9<1879::aid-cncr2820550906>3.0.co;2-1.
Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5. Twenty patients were evaluated after two cycles. Three (15%) are in complete remission 12, 16, and 53 weeks after therapy, respectively, and six (30%) experienced worthwhile partial remissions. This combined response rate of 45% is considerably better than that seen in single- or dual-agent chemotherapy. Toxicity was acceptable, and several patients received their therapy on an outpatient (ambulatory) basis. The one nonevaluable patient had radiotherapy for an isolated spinal metastasis and two courses of BELD. She is well and pain- and disease-free 56 weeks later. The median survival for all treated patients is 43 weeks, and the median follow-up time is now 63 weeks.
21例III期恶性黑色素瘤患者接受了为期5天的四联化疗方案（BELD），该方案包括第1天和第4天皮下注射博来霉素15mg，第1天和第5天静脉注射长春地辛（长春花碱酰胺）3mg/m²，第1天口服环己亚硝脲（洛莫司汀）80mg/m²，以及第1天至第5天静脉注射达卡巴嗪200mg/m²。两个周期后对20例患者进行了评估。3例（15%）分别在治疗后12周、16周和53周完全缓解，6例（30%）有明显的部分缓解。45%的联合缓解率明显优于单药或双药化疗。毒性是可接受的，几名患者在门诊接受了治疗。1例无法评估的患者因孤立性脊柱转移接受了放疗和两个疗程的BELD治疗。56周后她情况良好，无疼痛且无疾病。所有接受治疗患者的中位生存期为43周，目前中位随访时间为63周。
